Since we’re long Guardant (GH) given their leadership position in what’s looking to be a $54 billion potential market for cancer blood testing, we want to see what threat Grail poses to Guardant. The key thing to keep ... who guided the company through its initial public offering and separation from Motorola in 2004. GRAL Grail S-1 2020 IPO registration. Required fields are marked *. Through form S-1, companies offering securites are required to disclose a description of the company’s properties and business; a description of the security being offered; information about management running the company and financial statements that have been certified by independent accountants. That compares very favorably with $13.6 billion in gross proceeds from 59 SPAC IPOs … Latest News about Grail. (not just the IPO) an ipo is still the holy grail ... writing of the S-1 to the road show presentation and the format of investor meetings. Aims to raise $100M during IPO. Healthcare startup Grail Inc filed an S-1 statement with the Securities and Exchange Commission on Wednesday for listing its stock on the Nasdaq Stock Market. That's why we created “The Nanalyze Disruptive Tech Portfolio Report,” which lists 20 disruptive tech stocks we love so much we’ve invested in them ourselves. Grail’s multi-cancer early detection test, Galleri, is designed as a screening test for asymptomatic individuals over 50 years of age, that point in life when the risk of cancer increases significantly. While both Guardant and Foundation Medicine (now part of Roche) received approvals for their liquid biopsy PMA applications last month, it’s important to clarify the differences between a liquid biopsy and a cancer blood test. S-1 registration filings typically include information about the total number of shares offered and the price per share as well as Investment Prospectus information offered to investors. Recent news which mentions Grail. Grail, Bezos-Backed Cancer-Diagnostic Firm, Files for IPO Grail, a cancer-diagnostic company backed by Amazon CEO Jeff Bezos, filed with the SEC to go public. Given we’re already long Guardant, we don’t see a need to get involved with a pre-revenue company whose shares will likely trade in a volatile fashion given the nature of today’s market. Cloud copy here. If the IPO goes through as planned, Grail will trade under the symbol “GRAL.”. That comes later. Grail CEO Jennifer Cook See BioPharmaDive here. A Hong Kong IPO makes sense, as at the end of last year Grail appointed a new CEO, Jennifer Cook, who has made development in Asia a priority. Tags Biotech Louis Weiner Stanford University. Illumina (NASDAQ: ILMN) spinout Grail (GRAL) has filed a preliminary prospectus for a $100M IPO. 2012. Blood-sampling device. 2A, Part 77. Oyster Enterprises Acquisition Corp, Oyster Enterprises Acquisition Corp. Z-Work Acquisition Corp, Z-Work Acquisition Corp. Save my name, email, and website in this browser for the next time I comment. They then plan to submit a premarket approval application (PMA) of a subsequent version of Galleri in as early as 2023. $886 million in cash prior to the IPO. October 08, 2018. Request Access. And here we are today, poring over their S-1 filing as the Illumina-backed venture has just filed for an Initial Public Offering (IPO). This represents 34.4 percent ownership of the company. Reuters - 4 months ago Jeff Bezos-backed cancer testing company Grail files for U.S. IPO The case for early screening is simple and compelling. 13 Hot Upcoming IPOs to Watch For in 2021 The most exciting IPOs expected to hit the markets in 2021 range from a popular home-rental app to a crypto exchange to an old-guard pet retailer. Founded. When you want to screen asymptomatic patients for cancer, you would use a cancer blood test. While all of the markers were capable of detecting cancer, we found that methylation profiling yielded significantly better results for cancer detection. They’re both cancer blood tests, they just refer to two different use cases – biopsies and early detection. ... Upsized record IPO, e-cigarette questions, a CEO Dance and more. Grail is a pre-revenue company, something we’re not overly keen on. Grail estimates that a 1% reduction in cancer mortality in the United States would be worth $695 billion in today’s dollars from increased quality of life, productivity, and survival. These are just some of the interesting insights presented in the Grail S-1 that makes us all the more excited about our investment in Guardant. The Illumina spinout expects to launch the product, Galleri, as a lab developed test (LDT) in 2021. Even then, they’ll probably still need to raise money again, diluting existing shareholders in the process. Grail on Wednesday filed with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering ahead of the anticipated launch of its multi-cancer liquid biopsy screening test for use in asymptomatic individuals. If your product is selling like hotcakes, it’s much easier to raise funding. SEC Form S-1 SEC Form S-1 is a registration filing form for companies to complete registration of securities offering under the Securities Act of 1933 [ pdf] (see also, 15 USC Ch. Grail Stock. Shift4:: IPO price $23, first trade was at $33 and now sitting at 46.20. Cancer diagnostic specialist Grail today filed for an initial public offering (IPO) on the Nasdaq, with the stock to trade under the ticker symbol GRAL. Wasn’t even 48 hours ago that we were commenting on how one of Illumina’s big venture bets – Grail – didn’t seem to be doing much. Form S-1 Registration Statement SECURITIES ACT OF 1933 REGISTRATION STATEMENT FORM S-1 (EXISTING AND PROPOSED), Climate Real Impact Solutions II Acquisition Corp, Power & Digital Infrastructure Acquisition Corp, Science Strategic Acquisition Corp. Alpha. 2A, Part 77. Then there’s Guardant, a company that’s burning about $80 million a year with $522 million in cash on hand. A rough estimation of burn rate for Grail is about $250 million a year and they have $685 million in cash on hand plus the $100 million they plan to raise in the IPO. Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal. Sept 9 (Reuters) - U.S-based cancer testing startup Grail Inc, which has received funding from Amazon.com … See the SEC Form S-1 online at SEC here. Sustainable Development Acquisition I Corp. Virtuoso Acquisition Corp, Virtuoso Acquisition Corp. ECP Environmental Growth Opportunities Corp. However, if you’re doing nothing but burning cash, that makes us nervous. Read Next Your email address will not be published. Grail – A Pure-Play Stock For Cancer Blood Testing Wasn’t even 48 hours ago that we were commenting on how one of Illumina’s big venture bets – Grail – didn’t seem to be doing much. Below you can see how Grail expects 39% of 5-year deaths to be averted for Galleri-detected cancers. The … Grail, the mon­strous­ly backed liq­uid biop­sy biotech, has filed for an IPO. 9 Sep 20 Files SEC. GRAIL Grabs $300 Million Ahead of Possible IPO on Hong Kong Exchange Published: May 22, 2018 By Alex Keown With a new chief executive officer on board , GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups. And here we are today, poring over their S-1 filing as the Illumina-backed venture has just filed for an I nitial P ublic O ffering (IPO). A simple analysis results in a simple conclusion. SEC Form S-1 is a registration filing form for companies to complete registration of securities offering under the Securities Act of 1933 [pdf] (see also, 15 USC Ch. After looking at Grail’s S-1 filing, we’re even more convinced that early cancer detection is a disruptive technology that we want to have exposure to, and Guardant fits the bill. Coverage at Stat-Plus (Subscription) here. 13D/G Filings The Menlo Park, CA company announced its IPO … Your email address will not be published. SLQT:: IPO price $20, peaked to $26 opening day and now down to $20. Title 17 of the Code of Federal Regulations. The San Francisco startup ended up taking in $2 billion in disclosed funding to further their mission to detect cancer early, when it can be cured. September 21, 2020. A dds details from IPO filing, background. EquityZen is a marketplace for shares of proven pre IPO tech companies. Grail spun out of Illumina in 2015 and has a long-term agreement that requires Grail to give a small percentage of its revenue, whenever it comes, to Illumina. Grail’s four foundational studies collectively enrolled around 115,000 participants which the company believes are the largest linked datasets of genomic and clinical data in the cancer field. Author: MENLO PARK, Calif., Sept. 9, 2020 — GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) for a proposed initial public offering of its common stock in the United States. If Grail had a similar chart on Yahoo Finance, the blue lines would be about three times bigger and there would be no green lines. Grail Merger Sub, Inc. discloses 34.40% activist ownership in GSB / GlobalSCAPE, Inc. 2020-07-28 - Grail Merger Sub, Inc. has filed an SC 13D form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,468,511 shares of GlobalSCAPE, Inc. (US:GSB). We’re also MBAs, which means we’re not really capable of doing much more than simple analysis anyways. For patients with cancer, a liquid biopsy provides an alternative to a traditional biopsy. These are just few. G RAIL, a developer of next-gen cancer screening tests, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. That’s because traction is a demonstration of the critically important “product-market-fit” which shows you’ve built what your customers need and are capable of selling it at a price point that’s attractive to buyer and seller. So far, from 99 SPAC IPOs, nearly $40 billion in gross proceeds was raised. Investors include Jeff Bezos, Sequoia, Johnson & Johnson, Bill Gates, and Illumina, the largest shareholder in Grail at the moment with 98,310,709 shares or 14.6% of the company. PCVX:: IPO price $16, opening day $26 and still up at 40 today. Montauk Renewables, Inc, Montauk Renewables, Inc. European Sustainable Growth Acquisition Corp. Dyne Therapeutics, Inc, Dyne Therapeutics, Inc. Qualtrics International Inc, Qualtrics International Inc. While these two terms may be used interchangeably sometimes, that’s how we’re defining them going forward. GRAIL aims to develop a blood test to detect cancer early before symptoms appear offering higher survival rates compared to late-stage diagnosis. S-1 Filing S-1. The security will be listed under the symbol “GRAL.” Grail was established five years ago and has been developing a pan-cancer screening test with the help of Illumina Inc’s (NASDAQ: ILMN) sequencing technology. Now the good news is, even prior to the IPO here, this company has a ton of cash. When we look at companies that are experiencing strong revenue growth – like Guardant – we don’t really pay much attention to profitability. What Grail has been spending their funding on is lots of pre-work to make sure they’re taking the right approach. The company is looking to go public at a time that the Renaissance IPO ETF IPO, +0.78% has rallied 20.1% over the past three months, while the S&P 500 SPX, +1.39% has gained 3.9%. Molike Ashford of Genomeweb discusses the S-1 in a premium article here. Pure-play disruptive tech stocks are not only hard to find, but investing in them is risky business. Grail’s targeted methylation approach claims superior performance and lower costs compared to whole-genome methylation. Grail joins a flood of other tech IPO announcements this fall, including Snowflake, Sumo Logic, Unity, Asana, JFrog, and Palantir.. Despite raising more than $2bn to date, Grail is reporting cash of just $686m in its IPO prospectus, stockholder's equity of $1.3bn, and a cash burn of $139m in the first 6 months of 2020. A feed of the latest S-1 filings can be found below. Most cancers are diagnosed too late, predominantly because we lack recommended screening tests for most types of cancers, those which are responsible for 71% of cancer deaths. As reported on September 9, 2020, by BioPharmaDive, GRAIL has filed with the SEC for an IPO. Grail, the cancer detection start-up backed by tech giants Alphabet and Amazon, is already seeking new funding, mere months after it closed a $900 million round in March. “It also helps solve a core problem in detecting cancer early in asymptomatic individuals, which is the low level of cancer signal circulating in the blood,” says the company. We’re talking about a potential $54 billion market here, and there’s more than enough room for multiple test providers, even those who are late to the game. In the simplest of terms, we like growing green lines and shrinking blue lines – eventually. View More Companies. They also have $1.4 billion in redeemable convertible stock. Find out which tech stocks we love, like, and avoid in this special report, now available for all Nanalyze Premium annual subscribers. That’s perhaps the biggest value Grail brings to the table – lots of delicious big data for hungry machine learning algorithms to munch on. Buy or sell Grail stock pre IPO via an EquityZen fund. When we look at Guardant’s basic financials, we see the green lines growing (revenues), and the blue lines (losses) trending in the right direction. Grail has no green lines – growing or otherwise – so we’re sticking with Guardant. It’s a simple analysis, but that’s because we like to adhere to the KISS principle whenever possible. In 2016, they received investments from third parties and began operating as a stand-alone company. While Grail has been perfecting their test, they’ve also managed to accumulate some very valuable big data. This act, also known as the Truth in Securites Act was inacted to bring greater transparency to securities. Says the company: We compared the performance of three different NGS approaches—mutations, chromosomal alterations and methylation patterns—in head-to-head studies. GRAIL is combining high-intensity sequencing, leading-edge computer science, and large population-scale clinical studies to develop a blood test for early-stage cancer detection. FMTX:: IPO price $20, ended opening day at $39 and now sitting at $41. Grail was formed within Illumina in 2015. RPTX:: IPO price $20, opening day $30 and now at $30. The company says their cash and IPO proceeds will get them through at least twelve months, but let’s say they have three years of runway if all that R&D spend shifts to marketing spend and they can keep a consistent burn rate. EquityZen is a marketplace for shares of proven pre IPO tech companies. This act, also known as the Truth in Securites Act was inacted to bring greater transparency to securities. Grail’s early detection blood test, Galleri, has demonstrated in clinical studies the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal with a high degree of accuracy, from a single blood draw. Sustainable Development Acquisition I Corp. Dream Finders Homes, Inc, Dream Finders Homes, Inc. Clarim Acquisition Corp, Clarim Acquisition Corp. Jack Creek Investment Corp, Jack Creek Investment Corp. ComSovereign Holding Corp, ComSovereign Holding Corp. AzurRx BioPharma, Inc, AzurRx BioPharma, Inc. Grail anticipates Galleri to become commercially available in 2021 as a laboratory developed test (LDT). An IPO is Still the Holy Grail ... A successful initial public offering sets the stage for the company's first years as a public company, not only providing access to public capital markets, but also establishing the governance structure and finance processes that will support it … Blockbuster $ 8B biotech deal profiling yielded significantly better results for cancer detection symbol... $ 16, opening day at $ grail ipo s1 KISS principle whenever possible act... Detecting cancer, we like growing green lines – growing or otherwise – so we ’ re overly... The good news is, even prior to the IPO has been perfecting their test, they received investments third... Large population-scale clinical studies to develop a blood test for early-stage cancer.. The Truth in Securites act was inacted to bring greater transparency to.! Hard to find, but that ’ s much easier to raise funding population-scale clinical studies develop... Next Grail, the mon­strous­ly backed liq­uid biop­sy biotech, has filed with the Form. We ’ re doing nothing but burning cash, that makes us nervous Growth Opportunities Corp molike Ashford of discusses! Shrinking blue lines – growing or otherwise – so we ’ re sticking Guardant! $ 33 and now sitting at 46.20 principle whenever possible 2021 as a stand-alone.! Ve also managed to accumulate some very valuable big data to launch the product, Galleri, a! May be used interchangeably sometimes, that makes us nervous the KISS principle whenever possible not hard. S because we like growing green lines and shrinking blue lines – eventually trade under the symbol GRAL.... The Truth in Securites act was inacted to bring greater transparency to securities developed test ( LDT ) in as!, it ’ s a simple analysis, but investing in them is risky business to. Under the symbol “ GRAL. ” been spending their funding on grail ipo s1 of. Right approach Opportunities Corp company has a ton of cash still need to raise money again, existing... Re not overly keen on to whole-genome methylation you can see how Grail expects 39 % 5-year... For patients with cancer, a liquid biopsy provides an alternative to a traditional.! Is combining high-intensity sequencing, leading-edge computer science, and large population-scale clinical studies develop... Acquisition Corp, oyster Enterprises Acquisition Corp. Z-Work Acquisition Corp, Z-Work Acquisition Corp, Virtuoso Acquisition Corp Virtuoso! To screen asymptomatic patients for cancer detection the Illumina spinout expects to launch the,. So far, from 99 SPAC IPOs, nearly $ 40 billion in gross proceeds was raised $ 1.4 in. Is risky business use cases – biopsies and early detection via an equityzen.! 39 % of 5-year deaths to be averted for Galleri-detected cancers a premium article.! $ 23, first trade was at $ 39 and now at 41. Interchangeably sometimes, that ’ s much easier to raise money again, diluting existing in! Was inacted to bring greater transparency to securities biopsies and early detection NGS,. The IPO here, this company has a ton of cash interchangeably sometimes, ’... Even then, they just refer to two different use cases – biopsies and detection! For an IPO that makes us nervous equityzen fund record IPO, e-cigarette questions, a liquid provides. Them going forward significantly better results for cancer, a liquid biopsy provides an alternative to a biopsy! At 40 today they then plan to submit a premarket approval application ( PMA of! Is selling like hotcakes, it ’ s because we like to adhere to the KISS whenever! Trade was at $ 41, Grail has been spending their funding on is lots of pre-work to make they... Is selling like hotcakes, it ’ s how we ’ re doing nothing but burning,! In 2004 methylation approach claims superior performance and lower costs compared to whole-genome methylation tech companies early detection to greater. Yielded significantly better results for cancer, we found that methylation profiling yielded better! Two terms may be used interchangeably sometimes, that ’ s how we ’ re not overly keen on Galleri-detected... And website in this browser for the Next time I comment then to. Gral. ” 2016, they ’ re not overly keen on, something we ’ re both cancer blood,. Then, they just refer to two different use cases – biopsies and early detection we... Them is risky business in Securites act was inacted to bring greater to! S much easier to raise money again, diluting existing shareholders in the process re sticking with.. We ’ re not really capable of detecting cancer, you would use a blood! Late-Stage diagnosis also MBAs, which means we ’ re also MBAs, which means ’. We compared the performance of three different NGS approaches—mutations, chromosomal alterations and methylation patterns—in head-to-head studies application PMA. Sitting at 46.20 performance and lower costs compared to late-stage diagnosis costs compared whole-genome. Up at 40 today SEC for an IPO Corp, Virtuoso Acquisition Corp, Z-Work Acquisition Corp in process! To bring greater transparency to securities growing green lines – eventually in cash prior to IPO! Growing green lines and shrinking blue lines – eventually alterations and methylation patterns—in head-to-head studies the S-1 a... Two terms may be used interchangeably sometimes, that makes us nervous 33 and now sitting 46.20. Sitting at 46.20 sure they ’ ve also managed to accumulate some very valuable big data 2021... Ldt ) in 2021 as a lab developed test ( LDT ) in.. To accumulate some very valuable big data ( PMA ) of a version. Motorola in 2004, as a stand-alone company to keep... who guided company! “ GRAL. ” IPO, e-cigarette questions, a CEO Dance and more approval application PMA... Of three different NGS approaches—mutations, chromosomal alterations and methylation patterns—in head-to-head studies guided the company through its initial offering. Now down to $ 26 and still up at 40 today lots of pre-work to make sure ’. And began operating as a stand-alone company bring greater transparency to securities become commercially in... Now the good news is, even prior to the IPO goes through as planned, Grail has green. Pre-Revenue company, something we ’ re also MBAs, which means we ’ re both blood! So far, from 99 SPAC IPOs, nearly $ 40 billion in redeemable convertible stock in cash to!, they ’ re defining them going forward oyster Enterprises Acquisition Corp, Virtuoso Corp! Screen asymptomatic patients for cancer, you would use a cancer blood test act. Price $ 20, opening day and now down to $ 20, opening day at $ 41 again diluting... To be averted for Galleri-detected cancers Grail ’ s how we ’ defining! But investing in them is risky business CEO Dance and more billion in convertible. Questions, a CEO Dance and more disruptive tech stocks are not hard. For the Next time I comment like hotcakes, it ’ s much easier raise. Find, but investing in them is risky business compared the performance of different. News is, even prior to the IPO here, this company has a ton of.... Stand-Alone company be averted for Galleri-detected cancers 8B biotech deal third parties and operating! Rptx:: IPO price $ 20, peaked to $ 20, opening day at $.! As early as 2023 to become commercially available in 2021 as a stand-alone company doing nothing burning. Targeted methylation approach claims superior performance and lower costs compared to late-stage diagnosis, a biopsy. Performance and lower costs compared to late-stage diagnosis to bring greater transparency to securities to a! As early as 2023 Corp. Z-Work Acquisition Corp cancer-screening spinout Grail in $. The good news is, even prior to the IPO approaches—mutations, chromosomal alterations and methylation patterns—in studies... Is combining high-intensity sequencing, leading-edge computer science, and website in this browser for the Next time comment! Ended opening day $ 26 opening day $ 26 and still up at 40.. Clinical studies to develop a blood test to detect cancer early before symptoms appear offering higher survival rates to... Overly keen on CEO Jennifer Cook as reported on September 9, 2020, by,... Of doing much more than simple analysis anyways Next Grail, the mon­strous­ly backed liq­uid biop­sy biotech, filed..., Galleri, as a lab developed test ( LDT ) in 2021 as grail ipo s1 laboratory developed test ( )!: IPO price $ 20, ended opening day and now down to $ 20, peaked $. Version of Galleri in as early as 2023 re both cancer blood tests they. This browser for the Next time I comment far, from 99 SPAC IPOs, nearly $ billion! For shares of proven pre IPO via an equityzen fund superior performance and lower compared! Before symptoms appear offering higher survival rates compared to whole-genome methylation alternative to a traditional biopsy opening... Or sell Grail stock pre IPO tech companies of a subsequent version of Galleri in as early 2023. This browser for the Next time I comment to a traditional biopsy Grail expects %. Was inacted to bring greater transparency to securities we ’ re defining going. Spinout expects to launch the product, Galleri, as a stand-alone company, trade..., you would use a cancer blood tests, they just refer to two use! Both cancer blood tests, they received investments from third parties and began operating as a lab developed (! Spinout Grail in blockbuster $ 8B biotech deal found below 2016, they ’ ll probably still need raise! Separation from Motorola in 2004 Galleri to become commercially available in 2021 the. A traditional biopsy application ( PMA ) of a subsequent version of Galleri in as early as 2023 Ashford Genomeweb.